Alzheimer-type dementia and verbal memory performances: influence of selegiline therapy


In a double blind randomized crossover trial lasting 6 months selegiline, a selective MAO-B inhibitor, was tested against placebo for activity on verbal memory performances in Alzheimer-type dementia (DAT). Verbal memory was assessed with the Rey-Auditory-Verbal Learning Test at the start of treatment, at the time scheduled for crossover (90 days) and at… (More)
DOI: 10.1007/BF02226963

4 Figures and Tables


  • Presentations referencing similar topics